Articles By Alyson Martin
Amid the COVID-19 pandemic, a dilemma has hit the nascent industry: to close or not to close? We’re keeping track of how companies, and regulators, are reacting.
The House Committee on Veterans Affairs voted in support of medical cannabis access and research, sending two bills to the full House.
Research from Penn State looks at Denver, Colorado and suggests that legalization is, at worst, neutral, but likely positive for hospitality.
The Agency is specifically looking to collect “scientific data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds.”
Connecticut is surrounded by states that have legalized cannabis, or plan to. “We can't stick our heads in the sand,” said Governor Ned Lamont’s senior adviser.
As soon as lawmakers reconcile their versions, the bill heads to the governor’s desk.
At NASDA Winter Policy Conference, USDA says it’s loosening DEA lab testing requirement for hemp, and FDA signals openness to non-pharma CBD products.
“I think the increases are mainly driven by boomers who use weed aging into the 65 and older age bracket,” the study’s senior author told Cannabis Wire.
Tennessee State Senator Raumesh Akbari says all “controversial” bills take time, but with strong polling, the moment to legalize is now.